|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
114.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 5.03 | 6.97 | 5.48 | 2.66 | 1.60 | CEPS(Rs) | 7.61 | 9.22 | 7.11 | 4.20 | 3.05 | DPS(Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Book NAV/Share(Rs) | 44.38 | 39.35 | 32.38 | 26.90 | 24.24 | Tax Rate(%) | 23.28 | 25.29 | 27.66 | 12.59 | 30.78 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 6.22 | 7.01 | 8.02 | 6.31 | 6.57 | EBIT Margin(%) | 5.55 | 6.13 | 7.36 | 5.44 | 5.56 | Pre Tax Margin(%) | 3.09 | 4.36 | 4.65 | 2.39 | 2.09 | PAT Margin (%) | 2.37 | 3.26 | 3.37 | 2.09 | 1.45 | Cash Profit Margin (%) | 3.59 | 4.31 | 4.36 | 3.31 | 2.75 | Performance Ratios | | | | | | ROA(%) | 3.40 | 5.45 | 4.72 | 2.54 | 1.77 | ROE(%) | 12.01 | 19.42 | 18.49 | 10.39 | 6.85 | ROCE(%) | 14.53 | 18.35 | 17.58 | 11.80 | 12.14 | Asset Turnover(x) | 1.43 | 1.67 | 1.40 | 1.21 | 1.22 | Sales/Fixed Asset(x) | 3.33 | 3.44 | 3.13 | 2.80 | 2.50 | Working Capital/Sales(x) | 12.00 | 9.72 | 7.17 | 9.99 | 8.13 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.30 | 0.29 | 0.32 | 0.36 | 0.40 | Receivable days | 129.78 | 114.07 | 120.71 | 133.44 | 132.67 | Inventory Days | 34.17 | 27.96 | 48.21 | 65.26 | 65.40 | Payable days | 127.50 | 101.87 | 112.95 | 144.33 | 150.09 | Valuation Parameters | | | | | | PER(x) | 15.07 | 9.39 | 8.35 | 4.35 | 14.55 | PCE(x) | 9.96 | 7.09 | 6.44 | 2.75 | 7.66 | Price/Book(x) | 1.71 | 1.66 | 1.41 | 0.43 | 0.96 | Yield(%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EV/Net Sales(x) | 0.56 | 0.43 | 0.52 | 0.36 | 0.46 | EV/Core EBITDA(x) | 8.49 | 6.06 | 6.17 | 5.48 | 6.65 | EV/EBIT(x) | 10.13 | 7.10 | 7.01 | 6.70 | 8.20 | EV/CE(x) | 0.74 | 0.69 | 0.69 | 0.42 | 0.52 | M Cap / Sales | 0.36 | 0.31 | 0.28 | 0.09 | 0.21 | Growth Ratio | | | | | | Net Sales Growth(%) | -0.92 | 31.33 | 28.19 | 14.55 | 29.63 | Core EBITDA Growth(%) | -8.56 | 12.84 | 61.02 | 11.02 | 20.99 | EBIT Growth(%) | -10.21 | 9.33 | 73.50 | 11.98 | 23.78 | PAT Growth(%) | -27.82 | 27.06 | 106.32 | 65.57 | 45.70 | EPS Growth(%) | -27.82 | 27.06 | 106.32 | 65.57 | 45.70 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 1.07 | 0.78 | 1.25 | 1.36 | 1.21 | Current Ratio(x) | 1.18 | 1.29 | 1.34 | 1.19 | 1.22 | Quick Ratio(x) | 0.91 | 1.11 | 1.05 | 0.84 | 0.87 | Interest Cover(x) | 2.26 | 3.46 | 2.72 | 1.79 | 1.60 | Total Debt/Mcap(x) | 0.63 | 0.47 | 0.88 | 3.17 | 1.25 |
|
|
|
|
|
|